ISLAMABAD: In response to directives from Health Minister Nadeem Jan, the Drug Regulatory Authority of Pakistan (Drap) has intensified its action against pharmaceutical companies, canceling licences for three companies and suspending licences for six others due to substandard practices.
The accelerated measures by Drap come as a part of the government's commitment to ensuring the quality and safety of pharmaceutical products.
In a move to address concerns over adulterated and substandard drugs, the authority has suspended the registration of six pharmaceutical companies, revoked licences for three, and issued show cause notices to seven others.
The authority says that these actions have been sanctioned by the Drap Licencing Board, reflecting a decisive response to maintain the integrity of the pharmaceutical industry in Pakistan.
As part of ongoing efforts to enhance the quality of healthcare, the health minister has directed a particular focus on improving the supply chain of essential medications. This includes diabetes, epilepsy, and anti-cancer drugs, with an emphasis on facilitating the import of anesthesia injections and anti-cancer drugs for local manufacturing.
As per Drap officials, the licencing board has recently granted approval for the registration of influenza vaccines, heparin, and enoxaparin injections, to ensure reliability in pharmaceutical sector of the country.
The stringent actions taken by Drap reflect its commitment to upholding the highest standards in the pharmaceutical sector to safeguard the health and well-being of the public.
